Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 4/20 | 0.75 |
| ▸ | CNR2 | P34972 | 1/20 | 0.67 |
| ▸ | PANK3 | Q9H999 | 11/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104337 | 0.97 | RAB9A (0.75) | NPC1RAB9ACNR2PANK3SMN1; SMN2 | |
| SCHEMBL10253430 | 0.89 | CNR2 (0.63) | NPC1RAB9ACNR2PANK3SMN1; SMN2 | |
| SCHEMBL104605 | 0.87 | NPC1 (0.71) | NPC1RAB9APANK3SMN1; SMN2MAPT | |
| SCHEMBL6764523 | 0.87 | NPC1 (0.71) | NPC1RAB9APANK3SMN1; SMN2MAPT | |
| SCHEMBL10253152 | 0.87 | NPC1 (0.63) | NPC1RAB9ACNR2PANK3SMN1; SMN2 | |
| SCHEMBL10253029 | 0.87 | SMN1; SMN2 (0.66) | NPC1RAB9ACNR2PANK3SMN1; SMN2 | |
| SCHEMBL104586 | 0.86 | RAB9A (1.00) | NPC1RAB9APANK3SMN1; SMN2MAPT | |
| SCHEMBL14597010 | 0.86 | NPC1 (0.69) | NPC1RAB9APANK3SMN1; SMN2MAPT | |
| SCHEMBL10253135 | 0.85 | MAPT (0.71) | NPC1RAB9ACNR2PANK3SMN1; SMN2 | |
| SCHEMBL10253053 | 0.85 | CNR2 (0.71) | NPC1RAB9ACNR2PANK3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | NPC1 3876/4885RAB9A 1318/4885CNR2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.